Genkyotex’s NOX1&4 inhibitor strategy in liver fibrosis supported by new preclinical results
This research, conducted at University of California, San Diego, and University of California, Davis, supports the use of dual NOX1&4 inhibitors for the treatment of liver fibrosis, such